Pôle de Recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium.
Mol Diagn Ther. 2011 Dec 1;15(6):327-40. doi: 10.1007/BF03256468.
Acute or destabilized heart failure (DHF) is characterized by new or worsening signs and symptoms of heart failure leading to admission to an emergency department. Biomarkers may support the diagnosis, the prognosis and the management of DHF patients. The aim of this review article is to discuss and evaluate the clinical usefulness of both recognized and potential new biomarker tests for use in heart failure.
急性或不稳定型心力衰竭（DHF）的特征是新出现或恶化的心衰症状和体征，导致患者需要入住急诊部门。生物标志物可支持 DHF 患者的诊断、预后和管理。本文综述的目的是讨论和评估已被认可和潜在的新型心力衰竭生物标志物检测的临床应用价值。
